0

CMHC PULSE

Cardio Metabolic Health Congress – Official Blog

First Fully Mobile Continuous Glucose Monitor Gets FDA Approval

The US FDA has just approved the first and only fully mobile continuous glucose monitoring system for both adults and children as young as 2 years of age. The system sends glucose information in real time directly to an app on iOS-enabled devices, such as the iPhone, using Bluetooth technology. (Android applications are expected early next year.) The Dexcom G5 Mobile CGM System allows for up to 5 “followers,” such as parents or other caregivers, to remotely monitor the patient’s glucose levels and receive alerts about readings of concern.

To learn more on innovations such as these, join us at #CMHC 2015 on Saturday, October 24 for “Advances in Diabetes Technology,” to be presented during the Diabetes Management session by expert faculty speaker Anne L. Peters, MD.

Read more here.

AHA/ADA Updates Scientific Statement on CVD Prevention for Patients with Type 2 Diabetes

In an update to their previous 2007 statement, the AHA and ADA recently presented a review of the current literature and key clinical trials regarding blood pressure and glucose control, cholesterol management, aspirin therapy, and lifestyle modification for primary prevention of CVD in patients with type 2 diabetes. Both the AHA and ADA believed an update was in order due to the major changes that have occurred in the past several years in each of the “ABC” elements of diabetes care (HbA1c, blood pressure, and cholesterol), and because CVD remains the leading cause of death among patients with type 2 diabetes. Read more